Treats osteoporosis in postmenopausal women. ANDA 214512, held by Novitium Pharma. Alendronate Sodium.
As of Nov 16, 2026, ANDA 214512 (Alendronate Sodium), held by Novitium Pharma, was first approved by FDA on May 11, 2023, with 1 approved supplement and 0 published complete response letters.
Alendronate Sodium Oral Solution is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women Treatment to increase bone mass in men with osteoporosis Limitations of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, alendronate increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 11, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alendronate SodiumEQ 70MG BASE/75ML · solution;oral | Alendronate Sodium | Rx |
| Feb 3, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 11, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters